Bullish indicating open at $55-$60, IPO prices at $37
TG Therapeutics Inc (NASDAQ:TGTX). shares have reached a new 52-week high, touching $43.03 amid a surge in investor confidence. According to InvestingPro data, the company boasts an impressive gross profit margin of 88.3% and has achieved remarkable revenue growth of 40.8% over the last twelve months. The biopharmaceutical company, which focuses on developing treatments for B-cell malignancies and autoimmune diseases, has seen its stock price soar over the past year. The impressive ascent represents a 173.21% increase from the previous year, reflecting significant market optimism surrounding the company’s pipeline and growth potential. With a market capitalization of $6.2 billion and an overall Financial Health score of "GREAT" on InvestingPro, the company has demonstrated strong fundamentals backing its growth trajectory. This milestone underscores the strong performance of TG Therapeutics in a competitive industry, as it continues to advance its research and development efforts. Analysts maintain a bullish outlook, with comprehensive analysis and 18 additional key insights available through InvestingPro’s detailed research reports.
In other recent news, TG Therapeutics reported strong financial results for the fourth quarter of 2024, with a GAAP earnings per share (EPS) of $0.15, surpassing the consensus estimate of $0.08. The company’s revenue for the quarter reached $108.2 million, exceeding the forecast of $97.66 million, and contributing to a full-year revenue of $329.0 million. The biopharmaceutical firm’s product revenue was primarily driven by $310.0 million in net sales of Briumvi in the U.S. Cantor Fitzgerald reiterated an Overweight rating for TG Therapeutics, expressing optimism about the company’s potential, particularly for Briumvi, which saw strong patient enrollment early in 2025. The firm projects Briumvi’s U.S. revenue to reach $525 million in 2025, indicating confidence in continued market uptake. H.C. Wainwright maintained a Buy rating with a $55 price target, citing the company’s robust financial performance and future revenue projections. TG Therapeutics also ended 2024 with a solid cash position of approximately $311.0 million, suggesting strong financial health to support ongoing and future business initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.